Enjovo, a forward-thinking U.S.-based candy startup, is set to shake up the global confectionery industry with its unique approach to candy dispensing. The company has developed a patented ...

Amid a supply chain crisis, hospitals nationwide are preparing for potential surges in flu, COVID-19 and RSV cases this fall and winter. Respiratory infections led to more than 800,000 ...

A vaccine study participant developed a serious nerve disorder Company and FDA investigating the single adverse event report Novavax Inc. shares fell 19% after US regulators placed a hold on the ...

Novavax shares drop as much as 24%, the most intraday since July, after the company said the US FDA has placed a clinical hold on its application for a Covid-flu combination and stand-alone flu ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Nov 5 (Reuters) - Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 ...

Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and stand-alone flu inoculation, sending shares down sharply. The vaccine ...

Graeme Sloan / Bloomberg via Getty Images The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put two of the biopharma's programs on hold in response to a case of nerve disease from a former ...